Low dose nivolumab in metastatic mucosal melanoma: a case report

被引：0

作者：

Meraz-Brenez, Andres ^{[1
]}

Navarrete-Reyes, Ana P. ^{[2
]}

Ignacio-Alvarez, Eleazar ^{[3
]}

Ramirez-Anguiano, Georgina J. ^{[4
]}

Verduzco-Aguirre, Haydee C. ^{[1
]}

机构：

[1] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Hematooncol, Mexico City, DF, Mexico

[2] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Geriatr Serv, Mexico City, DF, Mexico

[3] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Nucl Med Serv, Mexico City, DF, Mexico

[4] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Otorhinolaryngol Serv, Mexico City, DF, Mexico

来源：

GACETA MEXICANA DE ONCOLOGIA | 2023年 / 22卷 / 03期

关键词：

Melanoma; Nivolumab; Geriatric oncology; Case report; Financial toxicity; FINANCIAL TOXICITY; CANCER; POPULATION; OUTCOMES;

D O I：

10.24875/j.gamo.23000030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We present the case of a 77-year-old man with metastatic mucosal melanoma, unable to afford standard doses of immunotherapy, who was treated with nivolumab at a lower dose of 0.5 mg/kg every 2 weeks. Drug activity was demonstrated through both objective tumor response and an immune-related adverse event. This suggests that a lower dose of nivolumab could be a viable alternative for patients with advanced mucosal melanoma at a high risk of treatment-related financial toxicity. Further research is needed to evaluate the efficacy of lower doses of immunotherapy, including its impact on long term outcomes.

引用

页码：140 / 145

页数：6

共 50 条

[31] Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma
Cao, Yenong
Afzal, Muhammad Zubair
Shirai, Keisuke
BMJ CASE REPORTS, 2021, 14 (08)
[32] Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma
Motoo Nomura
Isao Oze
Toshiki Masuishi
Tomoya Yokota
Hironaga Satake
Shunichiro Iwasawa
Ken Kato
Masashi Andoh
International Journal of Clinical Oncology, 2020, 25 : 972 - 977
[33] Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1470): : 85 - 87
[34] Efficacy of low dose nivolumab in recurrent / metastatic cervical cancer
Devabhaktuni, S.
Singh, A.
Georgy, J. T.
Antonisamy, J.
Thumaty, D. B.
John, A. O.
ANNALS OF ONCOLOGY, 2023, 34 : S1585 - S1585
[35] Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumab
Krueger, Oskar
Eisenburger, Robin
Tasdogan, Alpaslan
Zimmer, Lisa
Livingstone, Elisabeth
Hadaschik, Eva
Theurer, Sarah
Brodin, Berthold
Schadendorf, Dirk
Ugurel, Selma
FRONTIERS IN IMMUNOLOGY, 2024, 15
[36] Occurrence of Fatal Tubulopathy in an Old, Fit Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report
Georgery, Marine
Ram, Aurelie
Van Meerhaeghe, Tess
Drowart, Annie
Clause, Anne-Lorraine
Dal Lago, Lissandra
Rouviere, Heloise
CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 239 - 246
[37] Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
Mullally, W. J.
Cooke, F. J.
Crosbie, I. M.
Kumar, S.
Abernethy, V. E.
Jordan, E. J.
O'Connor, M.
Horgan, A. M.
Landers, R.
Naidoo, J.
Calvert, P. M.
FRONTIERS IN IMMUNOLOGY, 2022, 13
[38] Aspiration cytology of liver abscess uncovering metastatic rectal mucosal melanoma-A case report
Ng, Joanna K. M.
Leung, Howard H. W.
Li, Joshua J. X.
CYTOPATHOLOGY, 2024, 35 (01) : 163 - 166
[39] Metastatic Melanoma to the Rectum: A Case Report
Elbanna, Ahmed
Selim, Ranya
Hassan, Mona
Markus, Johnathon
Bukannan, Aymen
Bhan, Amit
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S833 - S834
[40] Metastatic melanoma of the jejunum - Report of a case
Saphir, O
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 1927, 4 (01) : 22 - 25

← 1 2 3 4 5 →